Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 19, 2017 – The FDA announced the discontinuation of Teva’s Zecuity (sumatriptan iontophoretic transdermal system).
Download PDF
Return to publications
